%0 Journal Article
%T Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma
%A Calogero Saieva
%A Camilla Delli Paoli
%A Carlotta Becherini
%A Cinzia Ciabatti
%A Cristina Muntoni
%A Daniela Greto
%A Domenico Campanacci
%A Francesca Terziani
%A Gabriele Simontacchi
%A Giovanni Beltrami
%A Guido Scoccianti
%A Icro Meattini
%A Isacco Desideri
%A Lorenzo Livi
%A Marco Perna
%A Mauro Loi
%A Monica Mangoni
%A Pierluigi Bonomo
%J Tumori Journal
%@ 2038-2529
%D 2018
%R 10.1177/0300891618765565
%X This retrospective study analyzes the safety and feasibility of concurrent chemoradiotherapy (CRT) in adjuvant treatment of soft tissue sarcoma (STS). A total of 158 patients with STS were retrospectively analyzed. Anthracycline-based computed tomography was performed in high-risk patients. Acute radiotherapy toxicity and chemotherapy-related toxicity were assessed according to the Common Terminology Criteria for Adverse Events 4.0; late radiotherapy toxicity was recorded according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria. Fifty-four (34.2%) patients received CRT. Mean follow up was 5.4 years (range .2每21.1 years). Local DFS每recurrence-free survival, distant DFS每relapse-free survival, and overall survival were 79.1%, 76.4%, and 64.6%, respectively, at last follow-up. Leukopenia occurred in 11.4% of patients. Skin acute toxicity developed in 60.1% of patients and determined interruption of radiotherapy treatment in 19 (12%) patients. Nineteen patients (12%) experienced moderate fibrosis (grade 2). Mild and moderate joint stiffness was recorded in 16 (10.1%) patients. Size ≡5 cm was the only predictor of local recurrence at multivariate analysis (hazard ratio [HR] 9.65, 95% confidence interval [CI] 1.28每72.83, p = .028). Age and stage resulted as independent distant relapse predictors (HR 4.77, 95% CI 1.81每12.58, p = .002 and HR 4.83, CI 1.41每16.57, p = .012, respectively). At Cox regression univariate analysis, Karnofsky Performance Status, size, and stage were significant survival predictors (HR 2.23, 95% CI 1.02每4.87, p = .045; HR 2.88, 95% CI 1.10每7.52, p = .031; HR 2.59, 95% CI 1.11每6.04, p = .028). Concurrent CRT is a well-tolerated treatment option with no additional toxicity compared to exclusive radiotherapy or sequential CRT
%K Soft tissue
%K sarcoma
%K adjuvant treatment
%K radiotherapy
%K chemotherapy
%K toxicity
%U https://journals.sagepub.com/doi/full/10.1177/0300891618765565